Share |
News

Verisante to Attend Conferences and Trade Shows in Australia, China and Europe


August 23, 2011 at 2:00 pm

VERISANTE AURA™, THE EARLY SKIN CANCER DETECTION DEVICE, WILL BE FEATURED THIS FALL IN A TELEVISION SPECIAL “SKIN DEEP IN THE NHS” ON BBC, ITV AND SKY TV

Vancouver, Canada: Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Franfurt:V3T) (the “Company” or “Verisante”), a leader in cancer imaging technology, announced today that President and CEO Thomas Braun will be attending the 2011 Annual Conference and Scientific Meeting of the Australasian College of Skin Cancer Medicine (“ACSCM”) from August 26-28 in Queensland. The theme of the 2011 meeting is Non-Melanoma Skin Cancers.


ACSCM has set the standard for skin cancer practice in Australia and New Zealand. It is the first formal professional body in Australasia to set rigorous standards of qualification in the practice of managing skin cancer. Members come from various backgrounds in medicine, including those from general practice, rural practice, general surgery, plastic surgery, pathology and dermatology backgrounds.


Mr. Braun will also be a keynote speaker at the 4th Annual Congress and Expo of Molecular Diagnostics (“CEMD-2011”) in Beijing from September 22-24. His presentation is titled Molecular Diagnostic Screening Test for Cancer and he will speak on the advancements in rapid Raman spectroscopy for detecting skin, lung, gastro-intestinal and cervical cancers.    

“These conferences and trade shows provide an excellent opportunity to introduce Verisante Aura™ to the wider medical device market,” said Thomas Braun, President and CEO of Verisante Technology, Inc. “With our listing on the Frankfurt Stock Exchange earlier this year and a CE mark and approval in Australia anticipated by the end of the year, we are accelerating efforts to bring awareness of Verisante Aura™ to potential customers, the global medical community and investors. CEMD-2011 is a timely event that will provide a strong introduction of our platform technology to an Asian audience.”

CEMD-2011 brings together academic experts and business specialists in molecular diagnostics from all over the world. In addition, Verisante will have an information and education booth at the following trade shows in Europe this fall:

20th Congress of the European Academy of Dermatology and Venereology (“EADV”)
Lisbon Congress Centre
October 20-24, 2011
Lisbon, Portugal   

The EADV is a non-profit association whose mission is to advance excellence in clinical care, research, education and training in the field of dermatology and venereology and to act as the advocate and educator of patients. Over 8,000 participants are expected at the EADV 20th Annual Congress.

Medica 2011
Messe Dusseldorf, the Canadian Pavilion
November 16-19, 2011
Dusseldorf, Germany

Medica is the world’s largest international medical trade fair with over 4,000 exhibitors from 60 nations presenting a complete range of new products, systems and services for in-patient and out-patient care.  Approximately 138,000 visitors from more than 100 countries are expected to attend this year’s conference.

SKIN DEEP IN THE NHS     

Verisante will be featured in a special segment titled Skin Deep in the NHS, which will air in the fall on Sky TV Channel 166, BBC and ITV. NHS stands for National Health Service in the U.K. The Verisante Aura™ for skin cancer detection will be discussed as the next generation in skin imaging technology.

The episode will be sent to all NHS general practitioners, consultant dermatologists and dermatology nurses. The Company’s segment will also be posted on Verisante’s website as soon as it is available.

Verisante Aura™ is a non-invasive device that uses proprietary technology to assist a medical professional in detecting skin cancer instantly, providing immediate and accurate results. 

For recent media coverage about Verisante Technology, Inc. please visit our media page at: http://www.verisante.com/news/media/.

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined on approximately 1,000 lesions at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Company is ISO 13485:2003 certified as a medical device manufacturer. While the Aura and Core have not yet been approved for sale, the Company anticipates Health Canada, European and Australian approval for the Aura™ in 2011.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:               
   
Thomas Braun, President and CEO                   
Verisante Technology, Inc.                   
Telephone: (604) 605-0507                   
Email: info@verisante.com                   
Website:  www.verisante.com                     
Youtube:  www.youtube.com/verisante                 
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top